
THE VANGUARD SCIENTIFIC LIBRARY

The Tesamorelin Question

A signal to the pituitary. A measurable change in visceral fat. A much narrower evidence base than the broad claims suggest.



Tesamorelin | An illustrated exploration of injectable pharmacology, published human trials, liver research, animal models, safety findings and unanswered questions.

Prepared for Vanguard Compound Research. General educational synthesis of existing literature; this is not original research, a peer-reviewed publication, a treatment protocol, or evidence validating a particular commercial product. No dosing, mixing or injection instructions are provided.

Evidence reviewed through 27 October 2026. Regulatory statements refer to the cited U.S. label. The abdominal illustration is conceptual, not a scan or a depiction of treatment results.

QUICK SUMMARY

The review in two minutes

The central finding is specific: changes in deep abdominal fat can occur without comparable changes in body weight.

What is best established?

Randomized trials support visceral adipose tissue reduction in adults with HIV-associated abdominal fat accumulation. Two pivotal studies enrolled more than 400 participants each. These findings concern a defined population and an imaging endpoint, rather than universal weight loss. [2, 3]

What is promising?

Smaller trials examined liver fat in people with HIV. A selected non-HIV obesity study, cognitive trials, and secondary muscle analyses extend the research questions, but their results do not establish broad clinical applications. [6, 7, 10, 11, 12, 13, 14]

What remains unresolved?

Whether favorable imaging changes produce fewer cardiovascular events, less advanced liver disease, better physical function or durable cognitive benefit remains a separate question. The studies discussed here cannot establish those outcomes across healthy populations.

The most useful reading rule: keep the molecule, formulation, population, comparator, endpoint and follow-up period attached to every result. Removing any of them can turn a valid finding into an unsupported claim.

Why the injectable focus matters

The direct human evidence reviewed here uses subcutaneous tesamorelin. It cannot be transferred to an oral product, an intravenous regimen, another peptide, or an untested combination simply because the names or proposed mechanisms overlap.

READING MAP

A guide to the chapters

01	The signal and the tissue	4-6
02	The pivotal trials and durability	7-8
03	Liver fat and molecular evidence	9-10
04	What animal models contribute	11
05	Human applications beyond the main indication	12-14
06	Safety and interpretation	15-16
07	Methods, questions and glossary	17-18
08	Linked references	19-20

How evidence is described

Direct clinical evidence tests tesamorelin in people. **Secondary analyses** revisit an existing trial and may generate hypotheses. **Mechanistic evidence** explains biological plausibility. **Indirect animal evidence** tests a pathway or model, not necessarily tesamorelin itself. These categories are descriptive; they are not a formal GRADE assessment.

Charts reproduce reported group summaries, not individual patient data. Schematics explain relationships and are explicitly labeled. Bracketed citations link to references; chapter rows above are clickable.

CHAPTER 01 / THE SIGNAL

A messenger upstream of GH

Tesamorelin stimulates a hormonal system; it does not replace every part of that system.

Growth hormone-releasing hormone (GHRH) acts at the pituitary, where growth hormone (GH) is released. Tesamorelin is a GHRH analogue. Downstream responses include increased insulin-like growth factor 1 (IGF-1) and changes in tissue metabolism. The clinical question is whether manipulating this signal improves a meaningful outcome, not simply whether the signal changes. [1, 5]




Figure 1. Simplified endocrine pathway. The return path represents feedback regulation; it does not mean pharmacological stimulation is self-limiting or risk-free. Conceptual illustration informed by [1, 5].

Why “natural release” is an incomplete explanation

A drug may stimulate endogenous secretion and still produce clinically important adverse effects. Biological familiarity is not a safety endpoint. Likewise, a rise in IGF-1 demonstrates a pharmacodynamic response; it does not, by itself, establish better health, improved recovery or longer life.

CHAPTER 01 / PHYSIOLOGY

Pulses, exposure and translation

In a small physiological study, 13 men received tesamorelin for two weeks, followed by withdrawal assessment. Investigators found augmentation of both basal and pulsatile GH secretion. This supports the proposed endocrine mechanism, but the sample and duration were far too limited to establish long-term benefit or uncommon harms. [5]

A PULSE PATTERN IS A MECHANISM, NOT A CLINICAL OUTCOME




Figure 2. Invented waveforms illustrate pulsatility only. They are not trial traces, concentration measurements or a prediction of individual response. [5]

Why route and formulation belong in the evidence

A clinical study evaluates a particular exposure produced by a particular preparation. An identical ingredient name on a vial cannot establish equivalent identity, potency, stability, sterility or bioavailability. Product equivalence requires its own evidence; published trials do not test Vanguard products.

The research summarized here concerns subcutaneous administration. There is no basis in this selected literature to assume that oral or intravenous delivery reproduces those results. This review therefore keeps injection research central without providing an administration protocol.

CHAPTER 01 / THE TISSUE

Abdominal fat is not one compartment




Figure 3. Stylized abdominal cross-section. Gold: subcutaneous adipose tissue beneath the skin. Pale teal: visceral adipose tissue around internal structures. Dark boundary: simplified abdominal musculature. Not to scale; organs are schematic.

Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) are anatomically different. A reduction in one compartment is not equivalent to the same percentage reduction in total body fat. Waist measurements and body weight also cannot identify exactly which tissue changed.

In the first pivotal study, VAT decreased while the reported changes in abdominal SAT were small. This helps explain why the research is about fat distribution rather than a simple downward movement on the scale. [2]

What the imaging endpoint can tell us

Computed tomography can quantify a defined abdominal fat area. That makes treatment groups more comparable than photographs alone. But a cross-sectional area in cm^2 is not a whole-body fat mass in kilograms, and an imaging response is not direct evidence of fewer heart attacks. Those endpoints require different studies.

CHAPTER 02 / THE PIVOTAL TRIALS

Two trials, a consistent direction

The group-level visceral fat signal was reproduced, although the magnitude differed.

Reported VAT change at approximately six months




Figure 4. Published percentage changes from two separate placebo-controlled trials. 2007: n=412 randomized; 2010: n=404. Bars show reported point estimates; uncertainty intervals are not reproduced. This is not a pooled analysis. [2, 3]

Falutz and colleagues reported a 15.2% VAT reduction with tesamorelin versus a 5.0% increase with placebo in 2007. In the subsequent trial, the respective changes were -10.9% and -0.6%. The differences between treatment and placebo are more informative than quoting only the treated-group reduction. [2, 3]

Strengths and limits

Randomization and placebo control make these findings substantially stronger than before-and-after photographs or uncontrolled reports. However, these trials enrolled adults with HIV and excess abdominal fat; they do not establish an equivalent response in an otherwise healthy person seeking cosmetic fat loss.

The first study was predominantly male. Population composition, eligibility criteria, background treatment and follow-up all matter when considering transfer to a different setting. A precise population-specific claim is scientifically stronger than a broader claim built from the same data. [2]

CHAPTER 02 / DURABILITY

What happens after treatment stops?

The extension study is central to interpretation. Continued tesamorelin exposure maintained the visceral fat effect, whereas VAT reaccumulated after withdrawal. This argues against describing a finite course as a permanent reset of abdominal fat biology. [4]

A response during exposure and a lasting response after withdrawal are different scientific outcomes. Both matter when assessing the practical value of a treatment.

A longer study is not automatically a long-term outcome study

An extension can show whether an imaging effect persists over additional months. It still may not be large or long enough to establish cardiovascular outcomes, cancer risk or the consequences of years of repeated exposure. Participants who continue into an extension may also differ from those who leave early.

The evidence behind a maintenance claim

A strong maintenance claim would describe how much of the original response remains, how many participants remain under observation, what happens after stopping, and whether the benefit matters to patients. Reporting only the best on-treatment time point leaves those questions unanswered.

What a future withdrawal study should measure

Useful outcomes would include serial VAT imaging, patient-reported symptoms and body-image concerns, metabolic markers, adverse effects, and the time course of any recurrence. A randomized withdrawal design can help distinguish a continuing pharmacological effect from a change that survives the end of treatment.

For website interpretation, “reduced visceral fat in controlled trials” is supportable within the studied setting. “Permanent fat removal” would make a different claim that these findings do not establish.

CHAPTER 03 / LIVER FAT

A promising extension of the story

A 2014 randomized study in 50 people with HIV and abdominal fat accumulation assessed liver fat as well as VAT over six months. The net effect on liver lipid-to-water percentage was -2.9 percentage points; VAT also declined relative to placebo. These were imaging outcomes, not evidence of prevention of liver failure. [6]

A trial selected for fatty liver

The 2019 multicentre trial enrolled 61 people with HIV and NAFLD. At 12 months, the estimated treatment effect on hepatic fat fraction was -4.1 percentage points (95% CI -7.6 to -0.7), equivalent to a 37% relative reduction versus placebo. [7]

LIVER FAT: ESTIMATED BETWEEN-GROUP EFFECT




Figure 5. The point and interval are from the adjusted treatment estimate in [7]. This is an absolute change in hepatic fat fraction, not a 4.1% relative reduction.

Fewer biopsy-evaluable participants showed fibrosis progression with tesamorelin (2/19) than placebo (9/24). This secondary result is encouraging but rests on small numbers. Less progression does not mean demonstrated fibrosis reversal. [7]

The study supports further liver research in this population. It does not establish prevention of cirrhosis or justify assuming identical benefits in non-HIV fatty liver disease. Older papers use NAFLD terminology; this review retains their study definitions rather than retrospectively reclassifying participants.

CHAPTER 03 / MOLECULAR EVIDENCE

What happens inside the liver?

A subsequent analysis used paired liver biopsies from the HIV-associated NAFLD trial to examine gene-expression patterns. It identified changes in hepatic pathways with tesamorelin, adding a molecular layer to the imaging observations. This was a mechanistic analysis of the same research cohort, not a second independent efficacy trial. [8]

From a tissue sample to a biological hypothesis

Transcriptomic analysis measures patterns of RNA expression. It can reveal coordinated pathway changes that would be invisible in a single blood test. It does not directly measure every protein, establish which cell type caused a change, or prove that a molecular shift will prevent disease years later.

One trial can generate many papers. Imaging, biopsy, gene-expression and subgroup publications can deepen understanding without multiplying the number of independent randomized experiments.

Does the finding apply to contemporary HIV treatment?

A later analysis examined participants using integrase inhibitor-based antiretroviral regimens. Visceral and hepatic fat findings favored tesamorelin in that subgroup. This improves relevance to an important treatment context, but a subgroup of an existing trial is smaller and does not replace a dedicated prospective comparison. [9]

How this should shape future work

The strongest next step would connect a prespecified molecular hypothesis to a validated clinical endpoint in a new cohort. Replication, adequate tissue sampling and transparent handling of multiple comparisons matter more than the number of biological pathways that reach a statistical threshold.

CHAPTER 04 / ANIMAL EVIDENCE

A pathway model is not a drug trial

Animal experiments help explain why the GH axis matters to liver metabolism. They do not supply a human treatment recommendation.

Fan and colleagues deleted the GH receptor specifically in mouse liver. The animals developed marked hepatic steatosis, with altered triglyceride synthesis and export. Restoring hepatic receptor signaling corrected triglyceride output, whereas IGF-1 infusion did not correct steatosis in that model. [15]

MOUSE PERTURBATION

Remove hepatic GH receptor

HUMAN INTERVENTION

Stimulate GH release upstream

Figure 6. The experiments perturb different levels of the system. A liver-specific gene deletion is not the inverse of a tesamorelin injection. Conceptual comparison based on [5, 15].

Follow-up work in this liver-specific knockout model described progression to fibrosis and adenoma formation. It supports the importance of tissue-specific GH signaling, but it does not demonstrate that tesamorelin prevents these outcomes in people. [16]

The translational boundary

Deleting a receptor changes the system profoundly and may alter development, feedback and compensatory pathways. Stimulating an intact adult axis is a different intervention. Species, sex, diet, tissue targeting and duration also affect interpretation.

These are **indirect mechanistic animal studies**, not direct animal efficacy studies of tesamorelin. They provide a biological rationale for testing hypotheses, while the human randomized trials remain the more relevant evidence for the molecule itself.

CHAPTER 05 / BEYOND HIV

Can the result extend to obesity?

Makimura and colleagues studied 60 abdominally obese adults selected for reduced GH secretion in a 12-month placebo-controlled trial. The estimated VAT treatment effect was -35 cm² (95% CI -58 to -12). Triglycerides and carotid intima-media thickness also improved, while body weight did not show a significant treatment effect. [10]

The inclusion criterion is part of the result: this was a selected group with reduced GH secretion, not a representative trial of everyone with obesity.

Why the finding is useful

This trial shows that the research question is not restricted to HIV. It provides a direct human signal in another defined physiological setting. That is a stronger basis for further testing than simply extrapolating from a pathway diagram.

Why the finding is not enough

A small selected trial cannot establish a broad obesity indication, identify all responders, or compare long-term clinical value with other interventions. Carotid wall thickness is a surrogate marker; improvement is not the same as a demonstrated reduction in cardiovascular events. [10]

What generalization would require

A broader program would need prospectively defined populations, sufficient representation across sex and age, clinically meaningful outcomes, longer follow-up, and active comparators relevant to the intended use. It would also need to resolve whether baseline endocrine measurements predict benefit reliably enough to guide selection.

The scientifically defensible application is a research hypothesis: selected people outside the HIV population may respond. The study does not establish routine use for general weight management, aesthetic fat loss or athletic conditioning.

CHAPTER 05 / COGNITION

An early signal, an unsettled question

Baker and colleagues randomized 152 older adults, including 66 with mild cognitive impairment, to tesamorelin or placebo for 20 weeks. The trial reported favorable cognitive effects. Its duration and endpoints do not establish prevention of dementia or reversal of Alzheimer disease. [11]

A newer pilot adds caution

A 2026 double-blind pilot assessed 22 adults across normal cognition and mild cognitive impairment over 10 weeks. Conventional analyses did not identify significant treatment-related changes in the study measures. Exploratory machine-learning analyses suggested possible differences in brain-related measures; those findings need independent validation. [12]

> A promising result in one trial and a null result in a smaller pilot should be presented together. Neither a positive exploratory model nor a nonsignificant comparison settles the clinical question.

What would count as a meaningful advance?

Cognitive research needs prespecified primary tests, adjustment for multiple comparisons, enough follow-up to assess persistence, and outcomes relevant to everyday function. A change in a test score, a change in brain connectivity and a reduced incidence of dementia are different endpoints.

Small studies can miss a real effect. They can also exaggerate an apparent one, particularly when many outcomes are explored. The correct response to this uncertainty is replication, not conversion of a mechanistic possibility into an anti-aging claim.

The cognition literature provides a reason for continued investigation. It does not supply established evidence for routine cognitive enhancement or dementia prevention with tesamorelin.

CHAPTER 05 / MUSCLE AND METABOLISM

Imaging changes are not performance

An exploratory analysis of earlier HIV trials examined trunk muscle density and area on CT. The tesamorelin group was restricted to participants with a substantial VAT response; 193 responders were compared with 148 placebo recipients with available images. Several muscle imaging measures improved. [13]

Why responder selection matters

Selecting treated participants according to a favorable post-treatment response changes the comparison. It is no longer the same question as comparing everyone originally randomized. The result can help identify related biological changes, but it may overstate what a new, unselected patient should expect.

CT density and area are useful tissue measurements. They do not directly demonstrate greater strength, improved walking ability, fewer falls or better training performance. Those outcomes would need to be tested explicitly. [13]

The glucose question

A 12-week randomized study in 53 people with type 2 diabetes found no significant between-group difference in relative insulin response. This is a limited short-term metabolic observation, not proof that tesamorelin is glucose-neutral for every person or safe indefinitely in diabetes. [14]

Three different questions: Does tissue composition change? Does physical function improve? Does long-term disease risk improve? A result for the first cannot be substituted for an answer to the other two.

For human applications, these studies are most useful as guides to future trial design: test functional outcomes, include the full randomized population, and monitor metabolic effects over clinically relevant periods.

CHAPTER 06 / SAFETY

The benefit cannot be read alone

The U.S. EGRIFTA WR label indicates reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, not weight-loss management. Long-term cardiovascular safety is not established. [1]

Risks identified in prescribing information

Key concerns include elevated IGF-1, glucose intolerance or diabetes, fluid retention, joint symptoms, hypersensitivity and injection-site reactions. Contraindications include active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy and hypersensitivity. The label calls for glucose and IGF-1 assessment and includes precautions for critical illness and relevant drug interactions. [1]

Why trials cannot answer every safety question

A trial designed to detect a change in fat area is not necessarily powered to detect a rare serious event. A selected population may exclude people at greatest risk. Short observation can also miss outcomes that take years to emerge. “No statistically significant difference” is therefore not interchangeable with “no risk.”

Formulations are not interchangeable evidence

The label specifies that EGRIFTA WR and EGRIFTA SV are not substitutable. Their formulation-specific instructions must not be inferred from a research paper or a vial strength. [1]

> This review evaluates published science. It does not verify the identity, sterility, stability, regulatory status or clinical equivalence of any Vanguard product or other research-use preparation.

Safety decisions require the current product information and individual clinical assessment. This chapter is a scientific overview, not a complete prescribing summary or a self-administration guide. Published efficacy is not a certificate of quality for a separately supplied injectable.

CHAPTER 06 / INTERPRETATION

How to read a persuasive result

1 / Keep the denominator visible

“Fat fell by 15%” is incomplete. Which fat compartment, which population, which time point, and compared with what? A within-group change includes influences that a placebo group helps account for. A relative percentage also differs from an absolute percentage-point change.

2 / Distinguish precision from importance

A confidence interval describes statistical uncertainty around an estimate under the model used. A P value does not show how much a patient benefits. A small, precise imaging effect may still leave the most important clinical outcome unanswered.

3 / Avoid counting the same participants twice

A primary trial, extension, molecular analysis and subgroup report may draw on overlapping participants. They answer different questions, but they are not four independent replications. This matters when a long reference list creates an impression of a much larger evidence base.

4 / Separate biology from application

Mechanistic plausibility helps choose a hypothesis. Controlled clinical evidence tests whether it works in a defined setting. Product-level validation asks another question: whether a particular preparation has the characteristics required to reproduce that exposure.

> A balanced website statement: “This review examines tesamorelin research in HIV-associated abdominal fat accumulation, emerging liver and metabolic applications, and the safety and evidence gaps that limit broader conclusions.”

The strongest presentation explains both the observed result and its boundary. It does not turn an imaging endpoint into a promise of disease prevention, permanent fat loss, muscle performance or longevity.

CHAPTER 07 / METHODS

How this review was assembled

This is a targeted narrative review prepared on 27 October 2026. Searches used tesamorelin with HIV, visceral adipose tissue, randomized trial, liver fat, NAFLD, obesity, cognition, muscle, glucose, GH pulsatility and animal mechanisms. PubMed, PubMed Central, primary journal records and official U.S. prescribing information were prioritized.

Selection emphasized pivotal controlled human trials, directly relevant smaller trials, withdrawal evidence, mechanistic secondary analyses, and clearly identified indirect animal models. Available abstracts, indexed study records and accessible full-text material were used. This was not an exhaustive systematic search, a preregistered review or a new meta-analysis.

Evidence handling

Published group summaries were reproduced without pooling unlike endpoints. No synthetic patient data or simulated treatment estimates were used. Conceptual figures are labeled. Citation numbers connect factual study descriptions to source records; confidence intervals appear where displayed estimates support them.

Limitations of this review

There was no independent dual screening or formal risk-of-bias scoring. Selective publication, multiplicity, attrition, sponsor involvement and overlapping cohorts may affect the literature. Readers should inspect each paper’s protocol, analysis population, funding and disclosures before drawing a high-stakes conclusion.

The most useful next research questions

Do VAT and liver-fat changes translate into durable patient benefit? Which baseline features predict response? What happens after withdrawal over longer intervals? Can liver findings be replicated outside HIV? Do muscle and cognitive signals improve daily function? What is the benefit-risk balance over years rather than months?

Editorial status: prepared for a commercial research website, not independently peer reviewed or endorsed by a regulator. The review presents published evidence; it does not create evidence for a product.

CHAPTER 07 / GLOSSARY

A small vocabulary for a large literature

GHRH / GH / IGF-1

Growth hormone-releasing hormone is an upstream signal; growth hormone is a pituitary hormone; insulin-like growth factor 1 is a downstream growth factor. They are related but not interchangeable.

VAT / SAT

Visceral adipose tissue lies within the abdominal cavity around organs. Subcutaneous adipose tissue lies beneath the skin.

Hepatic fat fraction

An imaging estimate of fat within the liver. It is distinct from a histological fibrosis score and from liver function.

NAFLD / MASLD

NAFLD is the older non-alcoholic fatty liver disease terminology used in several cited trials. MASLD denotes metabolic dysfunction-associated steatotic liver disease; criteria are not assumed identical.

Steatosis / fibrosis

Steatosis is fat accumulation. Fibrosis is scar tissue. Less liver fat does not automatically establish reversal of fibrosis.

Surrogate endpoint

A measurement used to reflect an aspect of disease biology. Its improvement does not necessarily establish fewer symptoms, complications or deaths.

Percentage points / relative percent

A change from 10% to 6% is a fall of 4 percentage points and a 40% relative reduction. This is an arithmetic example, not a trial result.

Secondary or exploratory analysis

An additional question examined within a study, often with less statistical protection or a narrower sample than the primary comparison.

LINKED REFERENCES / 1 OF 2

The source literature

Click a reference to open its primary record. Publication titles are retained for identification; capitalization is normalized where appropriate.

1. Theratechnologies / FDA. EGRIFTA WR (tesamorelin) prescribing information. Revised March 2025.
Official label; indication, formulation and safety.

2. Falutz J, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med.
Pivotal 26-week randomized trial. PMID: 18057338.

3. Falutz J, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr.
Second pivotal trial. PMID: 20101189.

4. Falutz J, et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS.
Extension and withdrawal evidence. PMID: 18690162.

5. Stanley TL, et al. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab.
Small human physiology study. PMID: 20943777.

6. Stanley TL, et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA.
Six-month liver and VAT study. PMID: 25038357.

7. Stanley TL, et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV.
Liver imaging and histology. PMID: 31611038.

8. Fourman LT, et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight.
Mechanistic analysis of the liver trial. PMID: 32701508.

LINKED REFERENCES / 2 OF 2

The source literature

Click a reference to open its primary record. Publication titles are retained for identification; capitalization is normalized where appropriate.

9. Russo SC, et al. (2024). Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS.
Subgroup analysis of the liver trial. PMID: 38905488.

10. Makimura H, et al. (2012). Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab.
Selected non-HIV obesity population. PMID: 23015655.

11. Baker LD, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol.
20-week cognitive trial. PMID: 22869065.

12. Stewart CE, et al. (2026). The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci.
10-week pilot; exploratory imaging. PMID: 42382101.

13. Adrian S, et al. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging.
Responder-restricted secondary analysis. PMID: 31237318.

14. Clemmons DR, Miller S, Mamputu JC. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One.
Short-term diabetes study. PMID: 28617838.

15. Fan Y, et al. (2009). Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem.
Indirect mechanistic mouse study. PMID: 19460757.

16. Fan Y, et al. (2014). Evolution of hepatic steatosis to fibrosis and adenoma formation in liver-specific growth hormone receptor knockout mice. Front Endocrinol.
Indirect mechanistic mouse follow-up. PMID: 25566190.

All sources accessed or verified 27 October 2026. This selected bibliography supports the scope of the narrative review; it is not a claim to exhaustive literature coverage.